ArticleClinical and translational radiation oncology2021

Patient reported toxicity and quality of life after hypofractionated high-dose intensity-modulated radiotherapy for intermediate- and high risk prostate cancer.

Jeroen Houben et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.